![John Volpone](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 1 M $ au 31/05/2026
John Volpone is currently Chief Operating Officer at X4 Pharmaceuticals, Inc. Formerly, Mr. Volpone was Director-Business Development at ZymoGenetics, Inc. and Senior Vice President-Strategic Operations at.
CTI BioPharma Corp.
Education includes an undergraduate degree from the University of Washington and an MBA from Seattle University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC. 0,31 % | 29/10/2025 | 289 881 ( 0,31 % ) | 1 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Directeur des opérations | 16/09/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| CTI BIOPHARMA CORP. | Responsable des Ressources Humaines | 01/10/2023 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology Engages in acquisition, development and commercialization of novel targeted therapies for blood-related cancers | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seattle University
 Seattle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
